Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class C
GOOG
|
+$820M |
| 2 |
Palo Alto Networks
PANW
|
+$358M |
| 3 |
Visa
V
|
+$355M |
| 4 |
CELG
Celgene Corp
CELG
|
+$339M |
| 5 |
Citigroup
C
|
+$325M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$722M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$356M |
| 3 |
Alibaba
BABA
|
+$345M |
| 4 |
EOG Resources
EOG
|
+$344M |
| 5 |
Canadian Pacific Kansas City
CP
|
+$321M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 19.08% |
| 2 | Consumer Discretionary | 17.25% |
| 3 | Communication Services | 14.3% |
| 4 | Technology | 13.13% |
| 5 | Financials | 9.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
INXN
501
DELISTED
Interxion Holding N.V.
INXN
| $11.2M | 0.01% |
414,476
-86,277
| -17% | -$2.39M |
|
502
Agios Pharmaceuticals
AGIO
$1.95B
| $11.2M | 0.01% |
158,943
+994
| +0.6% | +$97.2K |
|
503
Chord Energy
CHRD
$7.78B
| $10.9M | 0.01% |
1,254,058
-84,573
| -6% | -$886K |
|
504
Ocular Therapeutix
OCUL
$1.85B
| $10.8M | 0.01% |
770,232
+3,953
| +0.5% | +$79.4K |
|
|
FCSC
505
DELISTED
Fibrocell Science Inc.
FCSC
| $10.8M | 0.01% |
187,197
+10,195
| +6% | +$902K |
|
506
PUT
iShares Biotechnology ETF
IBB
$9.52B
| $10.5M | 0.01% |
+103,638
| New | +$12.4M |
|
|
HAPN
507
Happen Inc
HAPN
$2.23B
| $10.4M | 0.01% |
156,866
-173,374
| -52% | -$11.8M |
|
|
EE
508
DELISTED
El Paso Electric Company
EE
| $10.1M | 0.01% |
+274,300
| New | +$9.84M |
|
|
AFMD
509
DELISTED
Affimed
AFMD
| $10M | 0.01% |
162,061
-2,736
| -2% | -$339K |
|
510
Glaukos
GKOS
$9.9B
| $9.75M | 0.01% |
403,215
-177,415
| -31% | -$5.34M |
|
511
Renasant Corp
RNST
$3.96B
| $9.64M | 0.01% |
293,456
+202,100
| +221% | +$6.49M |
|
512
PUT
Ultragenyx Pharmaceutical
RARE
$2.56B
| $9.63M | 0.01% |
+100,000
| New | +$11.4M |
|
|
TVRD
513
Tvardi Therapeutics
TVRD
$19.7M
| $9.35M | 0.01% |
18,179
+11,900
| +190% | +$7.97M |
|
514
Xencor
XNCR
$1.59B
| $9.13M | 0.01% |
746,762
-8,743
| -1% | -$171K |
|
|
WBC
515
DELISTED
WABCO HOLDINGS INC.
WBC
| $9.03M | 0.01% |
86,153
-2,256
| -3% | -$264K |
|
|
AGTC
516
DELISTED
Applied Genetic Technologies Corporation
AGTC
| $8.86M | 0.01% |
674,362
-367,461
| -35% | -$6.1M |
|
517
Standard BioTools
LAB
$351M
| $8.82M | 0.01% |
1,087,650
-1,753,598
| -62% | -$27.6M |
|
518
Oneok
OKE
$56.1B
| $8.48M | 0.01% |
+263,407
| New | +$9.62M |
|
519
CALL
PTC Therapeutics
PTCT
$6.26B
| $8.01M | 0.01% |
+300,000
| New | +$12.8M |
|
|
DCOY
520
Decoy Therapeutics
DCOY
$2.09M
| $7.89M | 0.01% |
1
| – | – |
|
521
Regenxbio
RGNX
$648M
| $7.67M | 0.01% |
+355,344
| New | +$9.07M |
|
|
ACGN
522
DELISTED
Aceragen Inc
ACGN
| $7.27M | 0.01% |
15,973
+94
| +0.6% | +$41.6K |
|
|
TRVN
523
DELISTED
Trevena, Inc.
TRVN
| $7.25M | 0.01% |
+1,120
| New | +$5.53M |
|
524
Coherus Oncology
CHRS
$227M
| $7.13M | 0.01% |
355,998
+2,635
| +0.7% | +$80.2K |
|
525
Qualys
QLYS
$4.99B
| $7.12M | 0.01% |
250,263
-8,800
| -3% | -$295K |
|
Similar funds
Jennison Associates's Q3 2015 Portfolio in Review
As of Q3 2015, Jennison Associates held 813 positions worth $97.6B, down 11% from $109B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Jennison Associates's Q3 2015 filing shows 84 new, 272 increased, 353 reduced and 92 closed positions. Its largest new stake was Palo Alto Networks: 12,124,434 shares worth $348M. The largest sale was Gilead Sciences, an estimated $722M.
By sector, the portfolio is most concentrated in Healthcare at 19% of assets, down from 21% a quarter earlier, followed by Consumer Discretionary and Communication Services.
- Jennison Associates's largest Q3 2015 buy was Palo Alto Networks: 12,124,434 shares worth $348M.
- Jennison Associates added most to Alphabet (Google) Class C in Q3 2015, an estimated $820M increase.
- Jennison Associates's biggest Q3 2015 reduction was Gilead Sciences, cutting an estimated $722M.
- Jennison Associates fully exited KRAFT FOODS GROUP INC COM STK (VA) in Q3 2015, selling an estimated $144M.
- Jennison Associates's ten largest holdings make up 24% of its $97.6B portfolio in Q3 2015.
- Jennison Associates opened 84 new positions and closed 92 in Q3 2015.
- Jennison Associates's portfolio value fell 11% quarter-over-quarter to $97.6B.
Based on Jennison Associates's 13F filing for Q3 2015, filed 6 Nov 2015.